[{"address1": "1801 Augustine Cut-Off", "city": "Wilmington", "state": "DE", "zip": "19803", "country": "United States", "phone": "302 498 6700", "website": "https://www.incyte.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGF\u00dfR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.", "fullTimeEmployees": 2617, "companyOfficers": [{"maxAge": 1, "name": "Dr. Pablo J. Cagnoni M.D., Ph.D.", "age": 61, "title": "President and Head of Research & Development", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 2030103, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christiana  Stamoulis M.B.A.", "age": 53, "title": "Executive VP & CFO", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 1182527, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven H. Stein M.D.", "age": 57, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 1315385, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas  Tray", "age": 46, "title": "VP of Finance, Chief Accounting Officer & Controller", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael James Morrissey", "age": 60, "title": "Executive VP & Head of Global Technical Operations", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ben  Strain", "title": "Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Pamela M. Murphy", "age": 73, "title": "Vice President of Investor Relations & Corporate Communications", "yearBorn": 1951, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Paula J. Swain", "age": 66, "title": "Executive Vice President of Human Resources", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 611916, "exercisedValue": 4212209, "unexercisedValue": 19035774}, {"maxAge": 1, "name": "Dr. Vijay K. Iyengar M.D.", "age": 51, "title": "Executive VP of Global Medical Affairs, Product & Partnership Strategy", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 945900, "exercisedValue": 252813, "unexercisedValue": 673325}, {"maxAge": 1, "name": "Mr. James H. Lee M.D., Ph.D.", "title": "Group VP, Head of Inflammation & AutoImmunity Group", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 6, "overallRisk": 8, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-irhome", "maxAge": 86400, "priceHint": 2, "previousClose": 70.01, "open": 70.5, "dayLow": 69.73, "dayHigh": 71.7748, "regularMarketPreviousClose": 70.01, "regularMarketOpen": 70.5, "regularMarketDayLow": 69.73, "regularMarketDayHigh": 71.7748, "beta": 0.701, "trailingPE": 469.46664, "forwardPE": 10.485704, "volume": 1744902, "regularMarketVolume": 1744902, "averageVolume": 1897331, "averageVolume10days": 2171120, "averageDailyVolume10Day": 2171120, "bid": 70.29, "ask": 70.5, "bidSize": 300, "askSize": 1000, "marketCap": 13627959296, "fiftyTwoWeekLow": 50.35, "fiftyTwoWeekHigh": 83.95, "priceToSalesTrailing12Months": 3.213219, "fiftyDayAverage": 71.5294, "twoHundredDayAverage": 66.22995, "currency": "USD", "enterpriseValue": 11530229760, "profitMargins": 0.00769, "floatShares": 161318028, "sharesOutstanding": 193524000, "sharesShort": 5788151, "sharesShortPriorMonth": 5103263, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0299, "heldPercentInsiders": 0.020450002, "heldPercentInstitutions": 0.96791, "shortRatio": 4.24, "shortPercentOfFloat": 0.053000003, "impliedSharesOutstanding": 193524000, "bookValue": 17.823, "priceToBook": 3.9510744, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "earningsQuarterlyGrowth": 0.001, "netIncomeToCommon": 32615000, "trailingEps": 0.15, "forwardEps": 6.14, "lastSplitFactor": "2:1", "lastSplitDate": 967766400, "enterpriseToRevenue": 2.719, "enterpriseToEbitda": 64.924, "52WeekChange": 0.19721186, "SandP52WeekChange": 0.22894537, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "INCY", "underlyingSymbol": "INCY", "shortName": "Incyte Corporation", "longName": "Incyte Corporation", "firstTradeDateEpochUtc": 752423400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "72960770-e83b-3ec3-92c6-dbd8ced339a4", "messageBoardId": "finmb_332954", "gmtOffSetMilliseconds": -18000000, "currentPrice": 70.42, "targetHighPrice": 100.0, "targetLowPrice": 52.0, "targetMeanPrice": 78.255, "targetMedianPrice": 77.0, "recommendationMean": 2.25926, "recommendationKey": "buy", "numberOfAnalystOpinions": 24, "totalCash": 2158092032, "totalCashPerShare": 11.152, "ebitda": 177596992, "totalDebt": 60337000, "quickRatio": 1.834, "currentRatio": 1.973, "totalRevenue": 4241217024, "debtToEquity": 1.75, "revenuePerShare": 20.478, "returnOnAssets": 0.00863, "returnOnEquity": 0.0075499997, "grossProfits": 1484626048, "freeCashflow": 619452608, "operatingCashflow": 335336992, "earningsGrowth": 0.143, "revenueGrowth": 0.163, "grossMargins": 0.35005, "ebitdaMargins": 0.041869998, "operatingMargins": 0.2534, "financialCurrency": "USD", "trailingPegRatio": 0.4499, "__fetch_time": "2025-02-15"}]